Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function
NCT05907096 is registered in ClinicalTrials.gov with argenx as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function
- Lead sponsor
- argenx
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 17, 2024
- Completion date
- May 31, 2030
- Enrollment
- 103 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.